The Competition Commission is investigating insulin manufacturers Novo Nordisk and Sanofi Aventis, raising concerns about accessibility to diabetes care.
Amid controversy, the Independent Development Trust has appointed private contractors for oxygen plants at 55 hospitals, raising red flags about contractor qualifications and budget surges.